NCT06458439View on ClinicalTrials.gov

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

December 31, 2027

Conditions
Lymphoma, Non-HodgkinRelapsed Diffuse Large B Cell LymphomaRefractory Diffuse Large B-cell LymphomaHigh-grade B-cell LymphomaTransformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Epcoritamab

"* C1D1: fixed priming dose of 0.16 mg subcutaneous injection~* C1D8: fixed intermediate dose of 0.8 mg subcutaneous injection~* C1D15 onward: fixed full dose of 48 mg subcutaneous injection"

Trial Locations (1)

19104

RECRUITING

Abramson Cancer Center at the University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Genmab
All Listed Sponsors
collaborator

Genmab

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT06458439 - Epcoritamab-CAR T Cells for Large B-cell Lymphomas | Biotech Hunter | Biotech Hunter